Angiotensin II-receptor antagonist in the treatment of hypertension

Current Hypertension Reports

Volumn 7, Issue 4, 2005, Pages 287-293

  Volpe, Massimo ^a   Tocci, Giuliano ^a   Pagannone, Erika ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTIC PROTEINASE INHIBITOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; SARALASIN; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CLASSIFICATION; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT PLANNING;

EID: 24944476460     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0027-y     Document Type: Review

References (69)

1. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The HOT Study Group. Lancet 1998, 351:1755-1762.
2. Blood Pressure Lowering Treatment Trialists' Collaboration: Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000, 355:1955-1964.
3. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
4. Kannel WB, Ho K, Thom T: Changing epidemiological features of cardiac failure. Br Heart J 1994, 72(Suppl):S3-S9.
5. Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. Br Med J 1998, 317:167-71.
6. Ruilope LM, Coca A, Volpe M, Waeber B: ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens 2002, 15:367-371.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al.: For The LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
8. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. The SCOPE Study Group. J Hypertens 2003, 21:875-886.
9. Kjeldsen SE, Dahlof B, Devereux RB, et al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. JAMA 2002, 288:1491-1498.
10. Devereux RB, Dahlof B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension(LIFE) trial. Circulation 2004, 110:1456-1462.
11. Wachtell K, Olsen MH, Dahlof B, et al.: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. J Hypertension 2002, 20:405-412.
12. Lewis E, Hunsicker L, Clarke W, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). The Collaborative Study Group. N Engl J Med 2001, 345:851-860.
13. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan in Patients with type 2 Diabetes and Microalbuminuria (IRMA2) Study Group. N Engl J Med 2001, 345:870-878.
14. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. The Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Circulation 2002, 106:672-678.
15. Lindholm LH, Ibsen H, Dahlöf B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002, 359:1004-1010.
16. Pfeffer MA, McMurray J, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. N Engl J Med 2003, 349:1893-1906.
17. Teo K, Yusuf S, Sleight P, et al.: Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. The ONTARGET/TRANSCEND Investigators. Am Heart J 2004, 148:52-61.
18. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002, 360:60-75.
19. Pfeffer MA, Swedberg K, Granger CB, et al., for the CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003, 362:759-766.
20. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin II receptor blocker valsartan in congestive heart failure. N Engl J Med 2001, 345:1667-1675.
21. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomized trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
22. Bloom BS: Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998, 20:671-681.
23. Weber MA, Bakris GL, Neutel JM, et al.: Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2003, 5:322-329.
24. Dzau VJ, Mukoyama M, Pratt RE: Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994, 12(Suppl 2):S1-S5.
25. de Gasparo M, Catt KJ, Inagami T, et al.: International Union of Pharmacology. XXIII. The Angiotensin II receptors. Pharmacol Rev 2000, 52:415-472.
26. Berk BC, Vekshtein V, Gordon HM, Tsuda T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989, 13:305-314.
27. Geisterfer AA, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988, 62:749-856.
28. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth cells. J Clin Invest 1989, 83:1419-1424.
29. Stouffer GA, Owens GK: Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor. Circ Res 1992, 70:820-828.
30. Itoh H, Mukoyama M, Pratt RE, et al.: Multiple autocrine growth factors modulate vascular smooth muscle cells response to angiotensin II. J Clin Invest 1993, 91:2268-2274.
31. Taubman MB, Berk BC, Izumo S, et al.: Angiotensin II induces c-fos mRNA in aortic smooth muscle: role of Ca2+ mobilization and protein kinase C activation. J Biol Chem 1989, 264:526-530.
32. Naftilan AJ, Gilliland GK, Elderige CS, Kratt AS: Induction of the protooncogene c-jun by angiotensin II. Mol Cell Biol 1990, 10:5536-5540.
33. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al.: Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001, 38:1382-1387.
34. Raij L: Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 2001, 37:767-773.
35. Volpe M, Musumeci MB, De Paolis P, et al.: Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003, 21:1429-1443.
36. Griendling KK, Rittenhouse SE, Brock TA, et al.: Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986, 261:5901-5906.
37. Saward L, Zahradka P: Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997, 81:249-257.
38. Berk BC, Corson MA: Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997, 80:607-616.
39. Marrero MB, Schieffer B, Paxton WG, et al.: Direct stimulation of JAK/STAT pathway by the angiotensin II AT1 receptor. Nature 1995, 375:247-250.
40. Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979, 2:836-839.
41. SOLVD Investigators: Effect of enalapril on survival in patients with angiotensin II AT2 receptor subtype reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
42. Yusuf S, Sleight P, Pogue J, et al.: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
43. Biollaz J, Durr J, Brunner HR, et al.: Escape from mineralcorticoid excess: the role of angiotensin II. J Clin Endocr Metab 1982, 54:1187-1193.
44. Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin II-converting enzyme is an essential regulator of heart function. Nature 2002, 417:822-828.
45. Timmermans PB, Wong PC, Chiu AT, et al.: Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 1993, 45:205-211.
46. de Gasparo M, Levens NR: Pharmacology of angiotensin II receptors in the kidney. Kidney Int 1994, 46:1486-1491.
47. Zhuo J, Alcorn D, Allen AM, Mendelsohn FA: High resolution localization of angiotensin II receptors in rat renal medulla. Kidney Int 1992, 42:1372-1380.
48. Zhuo J, Alcorn D, Harris PJ, Mendelsohn FAO: Localization and properties of angiotensin II receptors in rat kidney. Kidney Int 1993, 44(Suppl 42):S40-S46.
49. Navar LG, Inscho EW, Majid SA, et al.: Paracrine regulation of the renal microcirculation. Physiol Rev 1996, 76:425-536.
50. Gigante B, Rubattu S, Russo R, et al.: Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 1997, 30:563-568.
51. Zhuo J, McGregor DP, Mendelsohn FAO: Comparative distribution of angiotensin II receptor subtypes in mammalian adrenal glands. In Adrenal Glands, Vascular System, and Hypertension. Edited by Vinson GP, Anderson DC. Melbourne: Journal of Endocrinology; 1996:53-68.
52. Zhuo J, Allen AM, Yamada H, et al.: Localization and properties of the angiotensin converting enzyme and angiotensin receptors in the heart. In The Cardiac Renin-Angiotensin System. Edited by Lindpaintner K, Ganten D. New York: Futura; 1994:63-68.
53. Kobayashi M, Furukawa Y, Chiba S: Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol 1978, 50:17-25.
54. Allen AM, McGregor DP, Chai SY, et al.: Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992, 32:339-344.
55. World Health Organization: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
56. Chobanian A, Bakris G, Black H, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289:2560-2571.
57. 2003 European Society of Hypertension: European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003, 21:1011-1053.
58. Weber MA, Julius S, Kjeldsen SE, et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
59. Julius S, Kjeldsen SE, Weber M, et al., for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
60. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
61. Niklason A, Hedner T, Niskanen L, Lanke J, for the Captopril Prevention Project (CAPPP) Study Group: Development of diabetes is retarded by ACE inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004, 22:645-652.
62. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
63. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
64. Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602.
65. Brenner BM, Cooper ME, de Zeeuw D, et al.: Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003, 26:683-687.
66. Barnett AH, Bain SC, Bouter P, et al., for the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
67. Granger CB, McMurray JJ, Yusuf S, et al., for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
68. McMurray JJ, Ostergen J, Swedberg K, et al., for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
69. Yusuf S, Pfeffer MA, Swedberg K, et al., for the CHARM Investigators and Committees: CHARM-Preserved Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.